Down-regulation of the serotonin transporter in hyperreactive platelets counteracts the pro-thrombotic effect of serotonin

Journal of Molecular and Cellular Cardiology

Volumn 52, Issue 5, 2012, Pages 1112-1121

  Ziu, Endrit ^a   Mercado, Charles P ^a   Li, Yicong ^a   Singh, Preeti ^a   Ahmed, Billow A ^a   Freyaldenhoven, Samuel ^a   Lensing, Shelly ^a   Ware, Jerry ^a   Kilic, Fusun ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Formation of active Rab4, Rab4 GTP; Paroxetine; Platelet; Serotonin signaling pathways; Serotonin transporter; Serotonylation; Thrombosis

Indexed keywords

COLLAGEN TYPE 1; PADGEM PROTEIN; PAROXETINE; SEROTONIN; SEROTONIN TRANSPORTER;

ADULT ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CAROTID ARTERY; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; SEROTONIN BLOOD LEVEL; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS;

ANIMALS; BLOOD PLATELETS; BLOOD PRESSURE; CALCIUM; CELL MEMBRANE; DOWN-REGULATION; MALE; MICE; MICE, INBRED C57BL; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET COUNT; RAB4 GTP-BINDING PROTEINS; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; THROMBOSIS; TRANSGLUTAMINASES;

MUS;

EID: 84862799314     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.02.004     Document Type: Article

References (46)

1. Rubenstein J.L. Development of serotonergic neurons and their projections. Biol Psychiatry 1998, 44:145-150.
2. Rudnick G. Active transport of 5-hydroxytryptamine by plasma membrane vesicles isolated from human blood platelets. J Biol Chem 1977, 252:2170-2174.
3. Vanhoutte P.M. Platelet-derived serotonin, the endothelium, and cardiovascular disease. J Cardiovasc Pharmacol 1991, 17(Suppl. 5):S6-S12.
4. Barter R., Pearse A.G. Mammalian enterochromaffin cells as the source of serotonin (5-hydroxytryptamine). J Pathol Bacteriol 1955, 69:25-31.
5. Brunk I., Blex C., Rachakonda S., Höltje M., Winter S., Pahner I., et al. The first luminal domain of vesicular monoamine transporters mediates G-protein-dependent regulation of transmitter uptake. J Biol Chem 2006, 281:33373-33385.
6. Holmsen H., Weiss H.J. Secretable storage pools in platelets. Annu Rev Med 1979, 30:119-134.
7. McNicol A., Israels S.J. Platelets and anti-platelet therapy. J Pharmacol Sci 2003, 93:381-396.
8. Linder L., Kiowski W., Bühler F.R., Lüscher T.F. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation 1990, 81:1762-1767.
9. Saxena P.R., Villalon C.M. Cardiovascular effects of serotonin agonists and antagonists. J Cardiovasc Pharmacol 1990, 15(Suppl. 7):S17-S34.
10. Brenner B., Harney J.T., Ahmed B.A., Jeffus B.C., Unal R., Mehta J.L., et al. Plasma serotonin levels and the platelet serotonin transporter. J Neurochem 2007, 102:206-215.
11. Kaumann A.J., Levy F.O. 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther 2006, 111:674-706.
12. Golino P., Maseri A. Serotonin receptors in human coronary arteries. Circulation 1994, 90:1573-1575.
13. Vikens K., Farstad M., Nordrehaug J.E. Serotonin is associated with coronary artery disease and cardiac events. Circulation 1999, 100:483-489.
14. van den Berg E.K., Schmitz J.M., Benedict C.R., Malloy C.R., Willerson J.T., Dehmer G.J. Transcardiac serotonin concentration is increased in selected patients with limiting angina and complex coronary lesion morphology. Circulation 1989, 79:116-124.
15. Ban Y., Watanabe T., Miyazaki A., et al. Impact of increased plasma serotonin levels and carotid atherosclerosis on vascular dementia. Atherosclerosis 2007, 195:153-159.
16. Yamada S., Akita H., Kanazawa K., et al. T102C polymorphism of the serotonin (5-HT) 2A receptor gene in patients with non-fatal acute myocardial infarction. Atherosclerosis 2000, 150:143-148.
17. Leosco D., Fineschi M., Pierli C., et al. Intracoronary serotonin release after high-pressure coronary stenting. Am J Cardiol 1999, 84:1317-1322.
18. Nebigil C.G., Choi D.S., Dierich A., et al. Serotonin 2B receptor is required for heart development. Proc Natl Acad Sci U S A 2000, 97:9508-9513.
19. Pino R., Cerbai E., Calamai G., et al. Effect of 5-HT4 receptor stimulation on the pacemaker current I(f) in human isolated atrial myocytes. Cardiovasc Res 1998, 40:516-522.
20. Cote F., Thevenot E., Fligny C., et al. Disruption of the nonneuronal tph1 gene demonstrates the importance of peripheral serotonin in cardiac function. Proc Natl Acad Sci U S A 2003, 100(23):13525-13530.
21. Pietraszek M.H., Takada Y., Takada A., et al. Blood serotonergic mechanisms in type 2 (non-insulin-dependent) diabetes mellitus. Thromb Res 1992, 66:765-774.
22. Walther D.J., Peter J.U., Winter S., et al. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell 2003, 115:851-862.
23. Shirakawa R., Yoshioka A., Horiuchi H., Nishioka H., Tabuchi A., Kita T. Small GTPase Rab4 regulates Ca2+-induced alpha-granule secretion in platelets. J Biol Chem 2000, 275:33844-33849.
24. Przyklenk K., Frelinger A.L., Linden M.D., Whittaker P., Li Y., Barnard M.R., et al. Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. J Thromb Haemost Feb. 2010, 8(2):331-340.
25. Nishihira K., Yamashita A., Tanaka N., Kawamoto R., Imamura T., Yamamoto R., et al. Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery. J Thromb Haemost Jan. 2006, 4(1):247-255.
26. Ahmed B.A., Jeffus B.C., Bukhari S.I., Harney J.T., Unal R., Lupashin V.V., et al. Serotonin transamidates Rab4 and facilitates its binding to the C terminus of serotonin transporter. J Biol Chem 2008, 283:9388-9398.
27. Abdelmalik N., Ruhé H.G., Barwari K., van den Dool E.J., Meijers J.C., Middeldorp S., et al. Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism. J Thromb Haemost 2008, 6:2168-2174.
28. De Groote L., Olivier B., Westenberg H.G. The effects of selective serotonin reuptake inhibitors on extracellular 5-HT levels in the hippocampus of 5-HT(1B) receptor knockout mice. Eur J Pharmacol 2002, 439(1-3):93-100.
29. Kreilgaard M., Smith D.G., Brennum L.T., Sánchez C. Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice. Br J Pharmacol 2008, 155(2):276-284.
30. Grynkiewicz G., Poenie M., Tsien R.Y. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985, 260(6):3440-3450.
31. Robinson N.A., Eckert R.L. Identification of transglutaminase-reactive residues in S100A11. J Biol Chem 1998, 273(5):2721-2728.
32. Fabbi M., Marimpietri D. Tissue transglutaminase is a caspase substrate during apoptosis. Cleavage causes loss of transamidating function and is a biochemical marker of caspase 3 activation. Cell Death Differ 1999, 6(10):992-1001.
33. Ware J., Russell S., Ruggeri Z.M. Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Proc Natl Acad Sci U S A 2000, 97:2803-2808.
34. Philipp C.S., Dilley A., Miller C.H., Evatt B., Baranwal A., Schwartz R., et al. Platelet functional defects in women with unexplained menorrhagia. J Thromb Haemost 2003, 1:477-484.
35. Bergmeier W., Schulte V., Brockhoff G., Bier U., Zirngibl H., Nieswandt B. Flow cytometric detection of activated mouse integrin alphaIIbbeta3 with a novel monoclonal antibody. Cytometry 2002, 48:80-86.
36. Szasz R., Dale G.L. COAT Platelets. Curr Opin Hematol 2003, 10(5):351-355.
37. Tseng Y.L., Chiang M.L., Huang T.F., Su K.P., Lane H.Y., Lai Y.C. A selective serotonin reuptake inhibitor, citalopram, inhibits collagen-induced platelet aggregation and activation. Thromb Res 2010, 126(6):517-523.
38. Guerrero J.A., Shafirstein G., Russell S., Varughese K.I., Kanaji T., Liu J., et al. In vivo relevance for platelet glycoprotein Ibalpha residue Tyr276 in thrombus formation. J Thromb Haemost 2008, 6(4):684-691.
39. Mercado C.P., Ziu E., Kilic F. Communication between 5-HT and small GTPases. Curr Opin Pharmacol 2011, 11(1):23-28.
40. Dubois C., Panicot-Dubois L., Gainor J.F., Furie B.C., Furie B. Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model. J Clin Invest 2007, 117(4):953-960.
41. Berry C.N., Lorrain J., Lochot S., Delahaye M., Lalé A., Savi P., et al. Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist. Thromb Haemost 2001, 85:521-528.
42. Ottervanger J.P., Stricker B.H., Huls J., Weeda J.N. Bleeding attributed to the intake of paroxetine. Am J Psychiatry 1994, 151:781-782.
43. Layton D., Clark D.W., Pearce G.L., Shakir S.A. Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England. Eur J Clin Pharmacol 2001, 57:167-176.
44. Dalton S.O., Johansen C., Mellemkjaer L., Nørgård B., Sørensen H.T., Olsen J.H. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003, 163:59-64.
45. de Abajo F.J., Rodriguez L.A., Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999, 319:1106-1109.
46. Mercado C.P., Kilic F. Molecular mechanisms of SERT in platelets: regulation of plasma serotonin levels. Mol Interv 2010, 10(4):231-241.